A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin, and US Sourced Avastin) in Healthy Male Subjects

Trial Profile

A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin, and US Sourced Avastin) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Samsung Bioepis
  • Most Recent Events

    • 25 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 25 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 25 Sep 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top